9-5318770-C-A
Variant names: 
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The XM_047423707.1(RLN2):c.-337-10502G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.394 in 151,600 control chromosomes in the GnomAD database, including 12,396 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: 𝑓 0.39   (  12396   hom.,  cov: 31) 
Consequence
 RLN2
XM_047423707.1 intron
XM_047423707.1 intron
Scores
 2
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  -0.533  
Publications
6 publications found 
Genes affected
 RLN2  (HGNC:10027):  (relaxin 2) This gene encodes a member of the relaxin subfamily and insulin superfamily of peptide hormones. In humans there are three non-allelic relaxin genes. This gene encodes multiple protein isoforms, at least one of which undergoes proteolytic processing. This processing generates relaxin A and B chains that are linked by disulfide bonds to form the mature peptide hormone. This hormone plays a role in the male and female reproductive systems and was initially noted for its role in pregnancy. This protein also plays broader roles in the cardiovascular system, including in the regulation of blood pressure and control of heart rate, and data from animal models shows that this protein may have anti-fibrotic and cardioprotective effects. [provided by RefSeq, Jul 2016] 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-1.03). 
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.448  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|
Frequencies
GnomAD3 genomes   AF:  0.395  AC: 59788AN: 151482Hom.:  12399  Cov.: 31 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
59788
AN: 
151482
Hom.: 
Cov.: 
31
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome   AF:  0.394  AC: 59796AN: 151600Hom.:  12396  Cov.: 31 AF XY:  0.395  AC XY: 29235AN XY: 74102 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
59796
AN: 
151600
Hom.: 
Cov.: 
31
 AF XY: 
AC XY: 
29235
AN XY: 
74102
show subpopulations 
African (AFR) 
 AF: 
AC: 
12377
AN: 
41270
American (AMR) 
 AF: 
AC: 
5820
AN: 
15236
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
1672
AN: 
3470
East Asian (EAS) 
 AF: 
AC: 
1072
AN: 
5154
South Asian (SAS) 
 AF: 
AC: 
2028
AN: 
4792
European-Finnish (FIN) 
 AF: 
AC: 
4880
AN: 
10496
Middle Eastern (MID) 
 AF: 
AC: 
94
AN: 
292
European-Non Finnish (NFE) 
 AF: 
AC: 
30682
AN: 
67878
Other (OTH) 
 AF: 
AC: 
835
AN: 
2102
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.502 
Heterozygous variant carriers
 0 
 1785 
 3570 
 5354 
 7139 
 8924 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 568 
 1136 
 1704 
 2272 
 2840 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
1103
AN: 
3474
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.